

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number: 3235-0076

Estimated average burden

hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Number)	Previous Names	None	Entity Type
0001541157	Celsus Therapeutics Plc.		<input checked="" type="checkbox"/> Corporation
Name of Issuer	Morria Biopharmaceuticals PLC		<input type="checkbox"/> Limited Partnership
Akari Therapeutics Plc			<input type="checkbox"/> Limited Liability Company
Jurisdiction of Incorporation/Organization			<input type="checkbox"/> General Partnership
UNITED KINGDOM			<input type="checkbox"/> Business Trust
Year of Incorporation/Organization			<input type="checkbox"/> Other (Specify)
<input checked="" type="checkbox"/> Over Five Years Ago			
<input type="checkbox"/> Within Last Five Years (Specify Year)			
<input type="checkbox"/> Yet to Be Formed			

2. Principal Place of Business and Contact Information

Name of Issuer			
Akari Therapeutics Plc			
Street Address 1		Street Address 2	
The Gridiron Building, One Pancras Squar		C/O Pearl Cohen Zedek Latzer Baratz UK L	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
London	UNITED KINGDOM	N1C 4AG	+44-203-318-3004

3. Related Persons

Last Name	First Name	Middle Name
Roshwalb	Gur	
Street Address 1	Street Address 2	
c/o Akari Therapeutics Plc	The Gridiron Building, One Pancras Squar	
City	State/Province/Country	ZIP/PostalCode
London	UNITED KINGDOM	N1C 4AG
Relationship: <input checked="" type="checkbox"/> Executive Officer <input checked="" type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Elefant	Dov	
Street Address 1	Street Address 2	
c/o Akari Therapeutics Plc	The Gridiron Building, One Pancras Squar	
City	State/Province/Country	ZIP/PostalCode
London	UNITED KINGDOM	N1C 4AG
Relationship: <input checked="" type="checkbox"/> Executive Officer <input type="checkbox"/> Director <input type="checkbox"/> Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Richardson	Clive	
Street Address 1	Street Address 2	
c/o Akari Therapeutics Plc	The Gridiron Building, One Pancras Squar	
City	State/Province/Country	ZIP/PostalCode
London	UNITED KINGDOM	N1C 4AG
Relationship: X Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Cohen	Mark	
Street Address 1	Street Address 2	
c/o Akari Therapeutics Plc	The Gridiron Building, One Pancras Squar	
City	State/Province/Country	ZIP/PostalCode
London	UNITED KINGDOM	N1C 4AG
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Prudo	Ray	
Street Address 1	Street Address 2	
c/o Akari Therapeutics Plc	The Gridiron Building, One Pancras Squar	
City	State/Province/Country	ZIP/PostalCode
London	UNITED KINGDOM	N1C 4AG
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Shaw	Allan	
Street Address 1	Street Address 2	
c/o Akari Therapeutics Plc	The Gridiron Building, One Pancras Squar	
City	State/Province/Country	ZIP/PostalCode
London	UNITED KINGDOM	N1C 4AG
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
Ungar	Stuart	
Street Address 1	Street Address 2	
c/o Akari Therapeutics Plc	The Gridiron Building, One Pancras Squar	
City	State/Province/Country	ZIP/PostalCode
London	UNITED KINGDOM	N1C 4AG
Relationship: Executive Officer X Director Promoter		

Clarification of Response (if Necessary):

Last Name**First Name****Middle Name**

Hill

James

Street Address 1**Street Address 2**

c/o Akari Therapeutics Plc

The Gridiron Building, One Pancras
Squar**City****State/Province/Country****ZIP/PostalCode**

London

UNITED KINGDOM

N1C 4AG

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture

Health Care

Retailing

Banking & Financial Services

X Biotechnology

Restaurants

Commercial Banking

Health Insurance

Technology

Insurance

Hospitals & Physicians

Computers

Investing

Pharmaceuticals

Telecommunications

Investment Banking

Other Health Care

Other Technology

Pooled Investment Fund

Manufacturing

Travel

Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?

Real Estate

Airlines & Airports

Yes

No

Commercial

Lodging & Conventions

Other Banking & Financial Services

Construction

Tourism & Travel Services

Business Services

REITS & Finance

Other Travel

Energy

Residential

Other

Coal Mining

Other Real Estate

Electric Utilities

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

5. Issuer Size

Revenue Range**OR****Aggregate Net Asset Value Range**

No Revenues

No Aggregate Net Asset Value

\$1 - \$1,000,000

\$1 - \$5,000,000

\$1,000,001 - \$5,000,000

\$5,000,001 - \$25,000,000

\$5,000,001 -
\$25,000,000

\$25,000,001 - \$50,000,000

\$25,000,001 -
\$100,000,000

\$50,000,001 - \$100,000,000

Over \$100,000,000

Over \$100,000,000

X Decline to Disclose

Decline to Disclose

Not Applicable

Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))

Investment Company Act Section 3(c)

Rule 504 (b)(1)(i)

Section 3(c)(1)

Section 3(c)(9)

Rule 504 (b)(1)(ii)

Section 3(c)(2)

Section 3(c)(10)

Rule 504 (b)(1)(iii)

Rule 505	Section 3(c)(3)	Section 3(c)(11)
X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)
	Section 3(c)(7)	

7. Type of Filing

X New Notice Date of First Sale 2015-09-18 First Sale Yet to Occur
Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security	Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? X Yes No

Clarification of Response (if Necessary):

Private placement consummated following closing of acquisition.

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient	Recipient CRD Number	None
MTS Securities, LLC	104059	
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number	X None
None	None	

Street Address 1

623 Fifth Avenue

City

New York

State(s) of Solicitation (select all that apply)
Check "All States" or check individual States

Street Address 2

14th floor

State/Province/Country

NEW YORK

Foreign/non-US

ZIP/Postal Code
10022

CALIFORNIA
CONNECTICUT
DELAWARE
ILLINOIS
MARYLAND
MASSACHUSETTS
NEW YORK

TEXAS

Recipient	Recipient CRD Number	None
Citigroup Global Markets Inc.	7059	
(Associated) Broker or Dealer	(Associated) Broker or Dealer CRD Number	X None
X None	None	

Street Address 1

Street Address 2

388 Greenwich Street

City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10013

State(s) of Solicitation (select all that apply)
 Check "All States" or check individual States

All States Foreign/non-US

- CALIFORNIA
- CONNECTICUT
- DELAWARE
- ILLINOIS
- MARYLAND
- MASSACHUSETTS
- NEW YORK
- TEXAS

13. Offering and Sales Amounts

Total Offering Amount \$75,000,000 USD or Indefinite
 Total Amount Sold \$75,000,000 USD
 Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. _____

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 28

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$5,250,000 USD Estimate
 Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

Placement agent fees paid to MTS Securities, LLC and Citigroup Global Markets Inc.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Akari Therapeutics Plc	/s/ Gur Roshwalb	Gur Roshwalb	Chief Executive Officer and Director	2015-09-28

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.